FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910347821> ?p ?o ?g. }

• W2910347821 abstract "Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). In a pooled analysis of data from 2 Phase 3 trials in patients (pts) with active PsA, tofacitinib 5 and 10 mg twice daily (BID) significantly improved American College of Rheumatology (ACR) 20 response rates vs placebo (PBO) (50.0, 53.0 vs 28.0%, respectively; p Objectives To compare the efficacy of tofacitinib 5 and 10 mg BID vs PBO in predefined pt subgroups based on differences in BL demographics, disease activity and concomitant medication. Methods This was an analysis of pooled efficacy data from 2 Phase 3, randomised, double-blind, PBO-controlled studies (OPAL Broaden [12 months; NCT01877668] and OPAL Beyond [6 months; NCT01882439]) in pts with active PsA (defined as ≥3 swollen and ≥3 tender joints). Pts in OPAL Broaden were tumour necrosis factor inhibitor (TNFi)-naive with an inadequate response (IR) to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD). Pts in OPAL Beyond had an IR to ≥1 TNFi. Pts were randomised to receive tofacitinib 5 or 10 mg BID, subcutaneous adalimumab 40 mg every 2 weeks (OPAL Broaden; data not included) or PBO. Pts continued to receive a stable dose of a single csDMARD. ACR20 response rates and LSM change from BL in HAQ-DI at Month 3 (primary endpoint data) were evaluated by subgroup category (demographic and disease characteristics at BL or at screening). Analyses were based on the full analysis set (table 1). Results In total, 238, 236 and 236 pts received tofacitinib 5 mg BID, 10 mg BID, or PBO, respectively. Across all subgroups analysed, tofacitinib 5 and 10 mg BID were generally associated with greater improvements at Month 3 in ACR20 and change from BL in HAQ-DI score than PBO (table 1). In pts classified as current smokers, slightly lower ACR20 response rates and similar changes from BL in HAQ-DI score to corresponding PBO at Month 3 were observed relative to never- or ex-smokers; however, the sample size was small. Statistical methods: ACR20 response was defined as achieving a≥20% improvement in ACR criteria components Missing ACR20 response was considered a non-response to treatment LSMs were calculated based on a mixed model for repeated measures without imputation for missing values ACR, American College of Rheumatology; BID, twice daily; BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DSS, Dactylitis Severity Score; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; LSM, least squares mean; MTX, methotrexate; N, number of patients in full analysis set (randomised and received ≥1 treatment dose); n, number of responders; N1, number of patients in the full analysis set by category of subgroup and treatment; N2, number of patients included in the repeated measures model by category of subgroup and treatment; NC, analysis not conducted; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; pts, patients; ROW, rest of world (Brazil, Mexico and Taiwan); SPARCC, Spondyloarthritis Research Consortium of Canada (enthesitis index) Conclusions In this analysis of pooled data from 2 Phase 3 studies in pts with active PsA, tofacitinib 5 and 10 mg BID consistently improved efficacy at Month 3 compared with PBO across all predefined subgroups evaluated, with the exception of current smoking; however, as this was not a pre-specified analysis and some subgroups (including smoking status) were small, interpretation should be made with caution. Reference [1] Nash P, et al. Arthritis Rheumatol2017;69(suppl 10):619. Acknowledgements Study sponsored by Pfizer Inc. Medical writing support was provided by K Nicholson of CMC and funded by Pfizer Inc. Disclosure of Interest F. Behrens Grant/research support from: AbbVie, Chugai, Novartis, Pfizer Inc, Prophylix, Roche, Consultant for: AbbVie, Biotest, BMS, Celgene, Chugai, Eli Lilly, Genzyme, Janssen, MSD, Novartis, Pfizer Inc, Roche, UCB, Speakers bureau: AbbVie, Biotest, BMS, Celgene, Chugai, Eli Lilly, Genzyme, Janssen, MSD, Novartis, Pfizer Inc, Roche, UCB, J. Gomez-Reino Grant/research support from: AbbVie, MSD, Pfizer Inc and Roche, Consultant for: Pfizer Inc, Speakers bureau: AbbVie, Biogen, Bristol-Myers Squibb, Janssen, MSD, Pfizer Inc and Roche, P. Nash Grant/research support from: AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, D. Gladman Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, O. FitzGerald Grant/research support from: AbbVie, BMS, Novartis, Pfizer Inc, Consultant for: Amgen, Celgene, Eli Lilly, Janssen, C. Ritchlin Grant/research support from: AbbVie, Amgen and UCB, Consultant for: AbbVie, Amgen, Celgene, Janssen, Novartis, Pfizer Inc, Sun and UCB, E. Kudlacz Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, J. Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, C. Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, A. Romero Shareholder of: Pfizer Inc, Employee of: Pfizer Inc" @default.
• W2910347821 created "2019-01-25" @default.
• W2910347821 creator A5000747220 @default.
• W2910347821 creator A5006685141 @default.
• W2910347821 creator A5012842018 @default.
• W2910347821 creator A5022208894 @default.
• W2910347821 creator A5027092636 @default.
• W2910347821 creator A5041379293 @default.
• W2910347821 creator A5049489990 @default.
• W2910347821 creator A5071926023 @default.
• W2910347821 creator A5077643606 @default.
• W2910347821 creator A5079480602 @default.
• W2910347821 date "2018-06-01" @default.
• W2910347821 modified "2023-10-16" @default.
• W2910347821 title "AB0921 Impact of baseline demographics, disease activity and concomitant medication on american college of rheumatology 20 response rate and health assessment questionnaire-disability index score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 phase 3 studies" @default.
• W2910347821 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3210" @default.
• W2910347821 hasPublicationYear "2018" @default.
• W2910347821 type Work @default.
• W2910347821 sameAs 2910347821 @default.
• W2910347821 citedByCount "0" @default.
• W2910347821 crossrefType "proceedings-article" @default.
• W2910347821 hasAuthorship W2910347821A5000747220 @default.
• W2910347821 hasAuthorship W2910347821A5006685141 @default.
• W2910347821 hasAuthorship W2910347821A5012842018 @default.
• W2910347821 hasAuthorship W2910347821A5022208894 @default.
• W2910347821 hasAuthorship W2910347821A5027092636 @default.
• W2910347821 hasAuthorship W2910347821A5041379293 @default.
• W2910347821 hasAuthorship W2910347821A5049489990 @default.
• W2910347821 hasAuthorship W2910347821A5071926023 @default.
• W2910347821 hasAuthorship W2910347821A5077643606 @default.
• W2910347821 hasAuthorship W2910347821A5079480602 @default.
• W2910347821 hasBestOaLocation W29103478211 @default.
• W2910347821 hasConcept C126322002 @default.
• W2910347821 hasConcept C141071460 @default.
• W2910347821 hasConcept C142724271 @default.
• W2910347821 hasConcept C16005928 @default.
• W2910347821 hasConcept C198451711 @default.
• W2910347821 hasConcept C203092338 @default.
• W2910347821 hasConcept C204787440 @default.
• W2910347821 hasConcept C27081682 @default.
• W2910347821 hasConcept C2776233030 @default.
• W2910347821 hasConcept C2776260265 @default.
• W2910347821 hasConcept C2777575956 @default.
• W2910347821 hasConcept C2778886723 @default.
• W2910347821 hasConcept C2779384505 @default.
• W2910347821 hasConcept C2780132546 @default.
• W2910347821 hasConcept C2780564577 @default.
• W2910347821 hasConcept C535046627 @default.
• W2910347821 hasConcept C71924100 @default.
• W2910347821 hasConceptScore W2910347821C126322002 @default.
• W2910347821 hasConceptScore W2910347821C141071460 @default.
• W2910347821 hasConceptScore W2910347821C142724271 @default.
• W2910347821 hasConceptScore W2910347821C16005928 @default.
• W2910347821 hasConceptScore W2910347821C198451711 @default.
• W2910347821 hasConceptScore W2910347821C203092338 @default.
• W2910347821 hasConceptScore W2910347821C204787440 @default.
• W2910347821 hasConceptScore W2910347821C27081682 @default.
• W2910347821 hasConceptScore W2910347821C2776233030 @default.
• W2910347821 hasConceptScore W2910347821C2776260265 @default.
• W2910347821 hasConceptScore W2910347821C2777575956 @default.
• W2910347821 hasConceptScore W2910347821C2778886723 @default.
• W2910347821 hasConceptScore W2910347821C2779384505 @default.
• W2910347821 hasConceptScore W2910347821C2780132546 @default.
• W2910347821 hasConceptScore W2910347821C2780564577 @default.
• W2910347821 hasConceptScore W2910347821C535046627 @default.
• W2910347821 hasConceptScore W2910347821C71924100 @default.
• W2910347821 hasLocation W29103478211 @default.
• W2910347821 hasOpenAccess W2910347821 @default.
• W2910347821 hasPrimaryLocation W29103478211 @default.
• W2910347821 hasRelatedWork W2413115384 @default.
• W2910347821 hasRelatedWork W2749276380 @default.
• W2910347821 hasRelatedWork W2751178115 @default.
• W2910347821 hasRelatedWork W2754043363 @default.
• W2910347821 hasRelatedWork W2754141291 @default.
• W2910347821 hasRelatedWork W2754454361 @default.
• W2910347821 hasRelatedWork W2755049090 @default.
• W2910347821 hasRelatedWork W2807716136 @default.
• W2910347821 hasRelatedWork W2894900585 @default.
• W2910347821 hasRelatedWork W2900635510 @default.
• W2910347821 hasRelatedWork W2947142015 @default.
• W2910347821 hasRelatedWork W2953386399 @default.
• W2910347821 hasRelatedWork W3033382998 @default.
• W2910347821 hasRelatedWork W3034156099 @default.
• W2910347821 hasRelatedWork W3041714706 @default.
• W2910347821 hasRelatedWork W3042207082 @default.
• W2910347821 hasRelatedWork W3043705891 @default.
• W2910347821 hasRelatedWork W3121825832 @default.
• W2910347821 hasRelatedWork W3164788343 @default.
• W2910347821 hasRelatedWork W3165658112 @default.
• W2910347821 isParatext "false" @default.
• W2910347821 isRetracted "false" @default.
• W2910347821 magId "2910347821" @default.
• W2910347821 workType "article" @default.